Denmark· DK-28106421020
Orladeyo
A berotralstat product containing berotralstathydrochlorid, registered in Denmark by BioCryst Ireland Limited. The same ATC class is registered in 17 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Berotralstat is registered in 17 of 19 countries.
Countries holding a registration under ATC B06AC06 (berotralstat), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 11 of them publish a price we can compare per daily dose
Berotralstat · ATC B06AC06
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of berotralstat costs, country by country.
Normalised to the WHO defined daily dose (0.15 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Berotralstat · price per daily dose (0.15 g)
USD · FX 28 Sept 2026
- CH Switzerland$576.89
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Berotralstathydrochlorid
- Manufacturer
- BioCryst Ireland Limited
- Country
- Denmark (DK)
- ATC code
- B06AC06
- ATC class
- Berotralstat
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106421020
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
209 interactions on record for berotralstat.
Graded by severity as the source publishes them — 66 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Berotralstat · interactions on record
209 records
- 66 severe
- 132 moderate
- 11 minor
Most severe, free to view
- RolapitantA04AD14severe
- NaloxegolA06AH03severe
- FidaxomicinA07AA12severe
- EliglustatA16AX10severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under B06AC06
Berotralstat, as other registers publish it.
- FinlandOrladeyoBioCryst Ireland Limited
- United StatesOrladeyoBioCryst Pharmaceuticals, Inc.
- FinlandOrladeyoBioCryst Ireland Limited
- FinlandOrladeyoBioCryst Ireland Limited
- FinlandOrladeyoBioCryst Ireland Limited
- FinlandOrladeyoBioCryst Ireland Limited
- United StatesOrladeyoBioCryst Pharmaceuticals, Inc.
- United StatesOrladeyoBioCryst Pharmaceuticals, Inc.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ca599216-c793-4817-825d-2e03a76ecd16 GET /v1/drugs/ca599216-c793-4817-825d-2e03a76ecd16?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "kapsler, hårde",
"source": "dkma",
"strength": "150 mg",
"auth_role": "MOD",
"dk_drugid": "28106421020",
"substance": "Berotralstathydrochlorid",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "44316"
}See everything about berotralstat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.